

Freedom of Information Act 2000**The Royal Cornwall Hospitals NHS Trust Response to Information request****Date Request Received: 14 01 2025****FOI Ref No: 27435****Requested/Response Information:**

diagnosis and treatment of Spinal Muscular Atrophy. Your answers to the following questions would be greatly appreciated.

Question 1. How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust? 0

We do not have any inpatients coded with any of these codes in this time period. We do not code our outpatient activity so could not identify these patients if they were being treated in an outpatient setting.

Question 2. How many patients have been treated in the last 4 months (September to December 2024) with the following products:

- Evrysdi (Risdiplam) - total patients 0
- Spinraza (Nusinersen) - total patients 0
- Zolgensma (Onasemnogene) - total patients 0
- Evrysdi (Risdiplam) – new* patients 0
- Spinraza (Nusinersen) – new* patients 0
- Zolgensma (Onasemnogene) – new* patients 0

*new patients are defined as patients who were not treated with any of Spinraza (Nusinersen), Evrysdi (Risdiplam) or Zolgensma (Onasemnogene) in the previous 4-month period (May to August 2024).

Question 3. Of the total patients treated in the last 4 months (September to December 2024) with Evrysdi (Risdiplam), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (May to August 2024).

0

Question 4. Of the total patients treated in the last 4 months (September to December 2024) with Zolgensma (Onasemnogene), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (May to August 2024).

0

Question 5. How many patients have been treated with Zolgensma (Onasemnogene) in the last 12 months (January to December 2024)?

0

Response:

Attachment(s):

Date Response sent: